Journal article
A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner
Abstract
Immune checkpoint therapy has shown great promise in the treatment of cancers with a high mutational burden, such as mismatch repair-deficient colorectal carcinoma (dMMR CRC). However, many patients fail to respond to immune checkpoint therapy. Using a mouse model of dMMR CRC, we demonstrated that tumors can be further sensitized to immune checkpoint therapy by using a combination of low-dose chemotherapy and oncolytic HSV-1. This combination …
Authors
El-Sayes N; Vito A; Salem O; Workenhe ST; Wan Y; Mossman K
Journal
International Journal of Molecular Sciences, Vol. 23, No. 3,
Publisher
MDPI
DOI
10.3390/ijms23031754
ISSN
1661-6596
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdenocarcinomaAnimalsAntineoplastic AgentsBasic-Leucine Zipper Transcription FactorsCell Line, TumorColorectal NeoplasmsCombined Modality TherapyDendritic CellsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsMice, Inbred C57BLMitomycinOncolytic VirotherapyRepressor ProteinsT-LymphocytesTranscriptomeMice